BioLife Solutions Financials - Benzinga

SPY766.67+0.32%QQQ741.75+0.52%BTC/USD84,439.00+0.97%DIA512.70−0.04%GLD383.26+0.10%TLT77.96−0.35%

BioLife Solutions Inc

BLFSNASDAQ

Trade with Public

Trade with Public

$39.26

0.040.1%

Last update: Sep 30, 9:44 AM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

BioLife Solutions Financials

BioLife Solutions (BLFS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
BioLife Solns Q2 Sales $28.466M Beat $27.683M Estimate

Benzinga Newsdesk

PRO
BioLife Solutions Affirms FY2026 Sales Guidance of $112.500M-$115.000M vs $112.942M Est

Benzinga Newsdesk

PRO
BioLife Solns Q1 Adj. EPS $0.04 Beats $0.02 Estimate, Sales $27.500M Beat $25.664M Estimate

Benzinga Newsdesk

BioLife Solutions Earnings Report: Q4 Overview

Benzinga Insights

PRO
BioLife Solutions Sees FY2026 Sales $112.500M-$115.000M vs $111.058M Est.

BioLife Solutions (NASDAQ:BLFS) sees FY2026 sales of $112.500 million-$115.000 million vs $111.058 million analyst estimate.

Benzinga Newsdesk

PRO
BioLife Solns Q4 Adj. EPS $0.04 Beats $(0.02) Estimate, Sales $24.764M Beat $24.082M Estimate.

BioLife Solns (NASDAQ:BLFS) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.02) by 281.82 percent. This is a 300 percent increase over losses of $(0.02) per share from the

Benzinga Newsdesk